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Background: Little is known about weekly variability in medication nonadherence both 
between and within persons.
Purpose: To characterize medication nonadherence across repeated, closely spaced occasions.
Methods: This prospective cohort study comprised four unannounced telephone assessment 
occasions, each separated by approximately 2 weeks. On each occasion, adult outpatients tak-
ing at least a single antihypertensive medication completed a measure of extent of, and reasons 
for, nonadherence.
Results: Two hundred and sixty-one participants completed 871 (83%) of 1,044 occasions. 
 Nonadherence was reported on 152 (17.5%) of 871 occasions by 93 (36%) of 261 participants. 
The most commonly endorsed reasons for nonadherence were forgetting (39.5%), being busy 
(23.7%), and traveling (19.7%). Among 219 participants completing at least three occasions, 
50% of the variability in extent of nonadherence was a result of within-person fluctuations, and 
50% was a result of between-person differences.
Conclusion: Interventions to reduce nonadherence should be informed by variability in the 
extent of nonadherence and specific reasons for nonadherence.
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Introduction
Nonadherence to antihypertensive medications is common, occurs for a number of dif-
ferent reasons, and results in suboptimal blood pressure control, cardiovascular events, 
mortality, and increased health care costs.1 Several interventions have been developed 
to reduce antihypertensive medication nonadherence. These interventions consisted of 
simplified dosing, education, motivational techniques, and skills training.2–4 Although 
some of these interventions improved adherence relative to usual care, effect sizes 
were small, leading to calls for more effective interventions.1
Interventions could be more effective if they considered both between- and within-
patient variability in nonadherence. Such knowledge can be obtained by repeatedly 
assessing individuals over the course of relatively closely spaced occasions. When such 
data are collected, they are often analyzed using a mean summary score (eg,  electronic 
drug monitoring data are averaged across days), which masks any variability in medi-
cation nonadherence.5 Nonadherence could fluctuate between individuals, as well as 
within individuals across measurement occasions as various contextual or personal 
challenges become more or less salient. Understanding variability in medication non-
adherence between and within patients would allow better matching of interventions 
to patient circumstances, thereby improving outcomes.





Intraindividual (ie, within-person) variability is defined 
as “relatively short-term changes that are construed as more 
or less reversible”.6 These short-term changes occur over 
minutes, hours, days, or weeks, depending on the construct 
of interest, study design, and measurement. In a study of 
medication nonadherence among older adults with arthritis, 
68% of the variability in monthly pill count data was a result 
of within-person fluctuations across occasions.7 We sought 
to extend such prior work using a different measure of non-
adherence (self-report) in the context of a different disease 
(hypertension) and during a different time period (weekly). 
To our knowledge, this is the first attempt to specifically char-
acterize intraindividual variability in weekly self-reported 
antihypertensive medication nonadherence.
In addition to characterizing between- and within-
person variability in nonadherence, we examined reasons 
for  nonadherence. Such information can inform the design 
and content of interventions to improve antihypertensive 
medication adherence. For instance, a different interven-
tion approach would be warranted if participants tended to 
miss medications repeatedly for the same reason than if they 
missed medications for different reasons across time. Many 
previously tested interventions to improve antihypertensive 
medication adherence took a one-size-fits-all approach, such 
as blister packs,8,9 reminders,10 copayment reduction,11 educa-
tion and/or psychological intervention,2,12 self-monitoring,13 
or regimen simplification.14 Even multifactorial interventions 
comprised a limited menu of intervention strategies that were 
provided to all participants.15 If a few reasons for nonadher-
ence (eg, regimen complexity or cost) were dominant across 
nonadherence occasions for all participants, then this approach 
would be sensible. In our previous cross-sectional study on 
antihypertensive nonadherence, however, reasons for nonad-
herence varied across individuals, with no single reason being 
endorsed by more than 27% of participants.16 Here we extend 
our previous research by examining the prevalence of reasons 
for nonadherence across repeated occasions.
Methods
Design overview, setting, and participants
This 8 week prospective cohort study conducted in 2011 
involved four telephone assessments, each separated by 
approximately 2 weeks. Participants were recruited from 
the Durham Veterans Affairs Medical Center in North 
Carolina, where institutional review board approval was 
obtained. Inclusion criteria determined by an electronic 
medical record data pull were age older than 40 years and 
documented diagnosis of hypertension. Inclusion criteria 
determined during the screening telephone call included 
prescription of at least a single antihypertensive medication, 
receiving the current antihypertensive regimen for at least 
3 months before enrollment, and receiving antihypertensive 
medications from the Durham Veterans Affairs Medical 
Center.  Exclusion criteria assessed during the screening tele-
phone call included cognitive impairment based on a six-item 
screen,17 unable to communicate in English or by telephone, 
resident in nursing home or receiving home health care, and 
health problem that would make it difficult to participate 
(as defined by patients).
Patients identified as eligible in the electronic data pull 
received by mail a recruitment letter that described the study 
and included a toll-free number to opt out. If patients did not 
opt out within 2 weeks of mailing recruitment letters, then 
a research assistant telephoned the patients to describe the 
study and further assess eligibility. Eligible patients were 
then consented verbally. Consented participants were told 
that they would receive the first assessment telephone call 
within 30 days, followed by three additional assessment tele-
phone calls, each separated by approximately 2 weeks. The 
target assessment frequency was every 14 days; a window of 
11–17 days was used to accommodate participant scheduling. 
 Telephone calls were made unannounced to reduce expec-
tancy effects (participants adhering better to their medication 
regimen because they knew they would be called). Participants 
received $10 for each completed assessment.
Outcomes
During call 1, we collected demographic data (age, sex, 
race/ethnicity, and education) and clinical data (number of 
years since diagnosis, drug names, and dosing instructions). 
 During calls 1–4, we assessed the extent of nonadherence 
and reasons for nonadherence, using a self-report measure.16 
The three extent-of-nonadherence items assess how often 
participants missed doses of their antihypertensive medica-
tions during the last 7 days. In a previous study, this measure 
had a single-factor structure in confirmatory factor analysis 
and was reliable (α=0.84). Furthermore, the measure dem-
onstrated discriminant validity via small correlations with 
social desirability,18 beliefs about medications,19 and consci-
entiousness and convergent validity via strong correlations 
with self-efficacy to take medications,20 habit strength, and 
the 8-item Morisky measure.21 Furthermore, our measure 
was significantly associated with blood pressure, whereas the 
Morisky measure was not. Although we originally validated 
this measure with an agreement response scale (strongly dis-
agree, disagree, neutral, agree, and strongly agree), we used a 
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frequency response scale (never, rarely, sometimes, often, and 
always) in the present study because frequency may correspond 
more closely to actual behavior.22 The instructions and item 
stems did not change. The 21-item reasons measure assessed 
21 distinct contributing factors for participants missing any 
of their antihypertensive medication during the last 7 days on 
a 5-point scale anchored by “not at all” and “very much”. As 
this portion of the measure includes causal indicators, internal 
consistency reliability and factor analysis are inappropriate, and 
the primary concern is content validity, which can be established 
via literature review or qualitative methods.16,23
statistical analyses
All analyses were performed with SPSS (version 20; IBM 
Corporation, Armonk, NY, USA) or SAS (PROC NLMIXED, 
version 9.2; SAS Institute Inc., Cary, NC, USA). We first 
provide baseline descriptive information for the full analytic 
sample. For each occasion for each participant, a summary 
nonadherence score was created by averaging responses 
across the three extent items. Internal consistency reliability 
(Cronbach’s α) was calculated for the extent of nonadherence 
scale at each occasion. Then, because the majority of responses 
were “never”, responses at each occasion were dichotomized 
as nonadherent (any response other than never for at least one 
extent of nonadherence item) or adherent (response of never 
for all three items) for each occasion. We also calculated the 
percentage of nonadherence occasions that each reason was 
endorsed (where a response other than “not at all” was pro-
vided) and provide descriptive information on the total number 
of reasons endorsed for each occasion for each participant.
To characterize intraindividual variability in nonadher-
ence, the remaining analyses were limited to participants 
completing 3 or 4 assessments, as such variability cannot be 
estimated with fewer observations.24 To decompose the vari-
ance in nonadherence into between- and within-person com-
ponents, we estimated a “null” (fully unconditional) logistic 
multilevel model (generalized linear mixed model) that 
included only fixed and random (subject-specific)  intercepts. 
This modeling approach was employed because occa-
sions were nested within individuals and the outcome was 
dichotomous.25–28 Between-person variability is represented 
by the random effect variance component, denoted σ2
bw
. This 
component captures differences between persons in the prob-
ability of nonadherence, with higher values implying greater 
heterogeneity between persons.
For logistic models, no within-person variance component 
could be estimated from the data. Rather, the  within-person 
variance is assumed constant and equal to the variance of 
an underlying standard logistic distribution (ie, π2/3≈3.29). 
Thus, the proportion of the total variance resulting from 







and the proportion resulting from within-person variation 




 is also known as the 
intraclass correlation coefficient (ICC) and ranges from 0 
to 1. An ICC of 0 implies that all persons have the same prob-
ability of nonadherence, and therefore, variability is entirely 
a result of random fluctuations in the binomial response, 
which occur with a fixed probability for all persons and 
 occasions. As the ICC increases, more of the total variability 
is explained by between-person differences in the likelihood 
of  nonadherence. At the upper limit, ICC =1, implying that all 
variability is a result of between-person differences and there 
is perfect correlation (no variability) in nonadherence across 
occasions within persons. Finally, an ICC ≈0.50 implies 
that the variability in the data is explained equivalently by 
between-person differences in the propensity to not adhere 
and by within-person fluctuations in nonadherence across 
occasions. We also qualitatively identified and described par-
ticipant nonadherence across completed occasions (always 
adherent; sometimes nonadherent, defined as nonadherent on 
at least one occasion; and always nonadherent).
Our a priori sample size of 250 patients and four time 
points were considered sufficient for variance decom-
position, as this is consistent with previous studies (eg, 
Almeida et al29). The mixed model uses all available cases 
and yields unbiased parameter estimates under a missing-
at-random assumption. Missing data were reduced, given 
our limitation of this analysis to individuals with 3 or 4 
completed occasions.
Results
Of the 1,197 patients to whom recruitment letters were mailed, 
862 were contacted. Of those, 323 provided verbal consent by 
telephone. Reasons for refusal included family issues, health 
reasons, lack of time, and lack of interest. Eighteen patients 
refused participation after consent, and nine were never called 
because of errors in the tracking database early in the study. 
Of the 296 participants who received at least one assessment 
telephone call, 27 were administered a version of the extent 
scale that used a different response scale; eight additional 
participants did not receive the first assessment telephone call 
because of errors in the tracking database. Data from these 
35 participants were excluded from analyses, resulting in a 
final analytic sample of 261 participants (Figure 1).
The 261 participants were 64 years old on average, and 
93% were men (Table 1). The sample was 51% white and 





48% black. Participants ranged in educational and financial 
status, with nearly 67% reporting some education beyond 
high school and 40% reporting that they had sufficient income 
to buy special things after paying bills.
Of the 1,044 possible occasions (261 participants mul-
tiplied by four time points), 871 (83.4%) were completed; 
142 participants (54.4%) had data from all four occasions, 
77 (29.5%) from three occasions, 30 (11.5%) from two occa-
sions, and 12 (4.5%) from one occasion, indicating good 
compliance to the study protocol. The sample size differed 
across occasions because of the inability to reach patients by 
telephone within the 11–17 day assessment window.
characterizing occasions: extent  
of nonadherence and reasons  
for nonadherence
Across the 871 completed occasions from 261 participants, 
the mean of extent of nonadherence (before dichotomizing) 
was 1.19 (standard deviation =0.48; median =1.0), skewness 
was 3.44, and kurtosis was 16.84, indicating that participants 
reported a low degree of nonadherence. The internal consis-
tency reliability for the three-item extent of nonadherence 
scale was 0.86 for occasion 1 (n=261), 0.78 for occasion 2 
(n=162), 0.94 for occasion 3 (n=222), and 0.90 for occasion 
4 (n=226). These values from the frequency response scale 
are comparable to the value of 0.84 obtained in prior work 
using an agreement response scale.16
Nonadherence (any response other than “never” on 
any extent of nonadherence item) was reported on 152 
(17.5%) of 871 occasions by 93 (35.6%) of 261 participants. 
Table 2  provides descriptive statistics for each reason for 
 nonadherence across the 152 occasions on which nonad-
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Refused after consent (n=18)
Not called after recruitment (n=9)
Full analytic sample
N=261
Figure 1 Participant flow diagram.
Table 1 Demographic characteristics of participants
Demographic characteristic Full analytic  
sample (n=261)
Age, mean (standard deviation) 63.9 (9.0)
Male, n (%) 243 (93)
race, n (%)
 White 133 (51)
 Black/African American 124 (48)
 Other 4 (1)
education, n (%)*
 high school or less 85 (33)
 some education beyond high school 65 (25)
 completed at least a 2 year college degree 110 (42)
Financial status, n (%)†
 Difficulty paying bills no matter what 38 (15)
 enough to pay bills because cut back on things 36 (14)
  enough to pay bills but little spare for special  
things
79 (31)
  After paying bills, still have enough for special  
things
104 (40)
Notes: Within a characteristic, numbers may not sum to the total because of missing 
data, and percentages may not sum to 100% because of rounding. Participants with 
missing data are excluded from percentage calculations. *One participant was 
missing data on education; †four participants were missing data on financial status.
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136 (17.0%) of 799 completed occasions by 82 participants 
(37.4%). Only 7 of these participants reported nonadherence 
on all completed occasions (“always nonadherent”); the other 
75 participants were nonadherent on some of their completed 
occasions (“sometimes nonadherent”). Results from the logis-
tic multilevel model indicated that 50% of the variability in 
extent of nonadherence was from between-person differences 
(ICC =0.50; standard error =0.05), with 50% of the variability 
resulting from within-person fluctuations across occasions. 
We were unable to examine intraindividual variability in the 
reasons for nonadherence further, given the small number of 
nonadherence occasions and few participants with a sufficient 
number of nonadherence occasions.
Discussion
In this study of self-reported antihypertensive medication 
nonadherence, the likelihood of nonadherence was explained 
as much by within-person variability across occasions as by 
between-person differences. Taken together, these findings 
suggest that important information about self-reported non-
adherence is lost if repeated assessments are not conducted 
or when repeated assessments are averaged to create a sum-
mary estimate. These findings also underscore the need to 
examine reasons for within-person variability in nonadher-
ence across occasions.
In this study, and in our prior cross-sectional study,16 no 
single reason was endorsed among the majority of patients. 
This might suggest that one-size-fits-all approaches (eg, 
value-based insurance design, as implemented in the Afford-
able Care Act to address cost, which was rarely endorsed) 
would have limited effectiveness. In contrast, offering a 
menu of intervention approaches for all possible reasons 
for nonadherence may not be feasible or cost-effective. 
Accordingly, researchers, providers, and insurers may need 
to prioritize which reasons for nonadherence are addressed 
in multifactorial interventions, offering solutions for reasons 
that are more commonly endorsed across repeated occasions 
such as forgetting, traveling, and running out of medication. 
Variability in reasons could be addressed if an intervention 
involved frequent assessments of extent of, and reasons for, 
nonadherence.
The current findings have implications for the design of 
interventions to reduce antihypertensive nonadherence. In 
studies evaluating such interventions, nonadherent patients 
are targeted so that there is room for improvement in 
 outcomes. As seen in this study, identification of  nonadherent 
patients is complicated by the reporting of nonadherence on 
some occasions and not others. Therefore, a run-in period 
Table 2 endorsement of reasons for nonadherence on nonadher-
ence occasions
Reason for nonadherence Nonadherence occasions 
endorsed (n=152)
i forgot 39.5%
i was busy 23.7%
i was traveling 19.7%
i ran out of medication 15.1%
i came home late 14.5%
i was with friends or family members 13.8%
They make me need to urinate too often 10.5%
The medication caused some adverse 
effects
9.2%
i worried about taking them for the  
rest of my life
9.2%
i was afraid they might affect my sexual 
performance
9.2%
i was in a public place 7.2%
i was afraid the medication would  
interact with another medication i take
6.6%
i was feeling too ill to take them 5.9%
They cost a lot of money 5.9%
The time to take them was between  
my meals
5.3%
i felt i did not need them 3.3%
i was afraid of becoming dependent  
on them
2.6%
My blood pressure was too low 2.6%
i did not have any symptoms of high  
blood pressure
2.6%
i had other medications to take 2.0%
i was supposed to take them too many  
times a day
0.7%
Notes: reasons for nonadherence are examined for nonadherence occasions, which 
are occasions in which any degree of nonadherence was reported (ie, a response 
other than “never”) on at least one extent of nonadherence item (of 152 total 
nonadherence occasions). Endorsement of a reason is defined as responding at least 
2 on 1–5 scale, where 1= not at all and 5= very much.
endorsed reason, reported on 60 (39.5%) of the 152 occasions, 
followed by being busy (n=36, 23.7%), traveling (n=30, 
19.7%), running out of medication (n=23, 15.1%), and com-
ing home late (n=22, 14.5%). The remaining reasons were 
cited on 0.7%–13.8% of nonadherence occasions. Across all 
nonadherence occasions, the number of reasons endorsed 
by a participant ranged from 0 to 21 (mean =2.09; standard 
deviation =2.53; median =1.0). On 31 nonadherence occasions 
(20.4%), no reason for nonadherence was endorsed, despite 
the patient reporting nonadherence on the extent scale.
intraindividual variability in extent  
of nonadherence
We examined the extent of nonadherence among the 
219 participants completing 3 or 4 measurement  occasions. 
In this subsample, any nonadherence was reported on 





including multiple assessments of nonadherence could 
be used to identify individuals who would benefit from 
intervention using some criterion (eg, nonadherent on at 
least 20% of occasions), as has been done with electronic 
drug monitoring.30–32 The eligible patients could be further 
classified on the basis of the extent of nonadherence into 
consistently nonadherent or variably nonadherent, which 
could suggest different intervention strategies.
Observational data on intraindividual variability in extent 
of nonadherence may also inform intervention dosing. With 
a large number of occasions, one could calculate the mean 
lag between nonadherence occasions within persons, as well 
as variability about this mean, to determine how frequently 
to intervene and whether intervention frequency should be 
tailored (in the case of great variability around the lag) or 
untailored (in the case of less variability around the lag).
Our results also have important clinical implications. 
Because patients may be adherent at one time point and not 
another, it is important to assess and monitor nonadherence 
across time to inform clinical decision making, as is done 
with clinical parameters such as blood pressure.33 Including 
a valid, reliable measure of medication nonadherence in 
the electronic medical record, a goal of the National Can-
cer Institute’s Grid-Enabled Measures Database,34 could 
facilitate repeated assessments at the point of care. Indeed, 
self-reported medication nonadherence could be considered 
an additional vital sign.
This study has some limitations. First, the small number 
and spacing of occasions may have led to biased estimates 
of intraindividual variability. In addition, nonadherence was 
reported infrequently, limiting assessment of  variability. 
 Second, the frequency response scale for extent of non-
adherence yielded few positive values, compelling us to 
dichotomize the data. However, given that there were few 
observed values greater than 1 (“never”), collapsing the data 
into binary categories should not result in a major loss of 
information. Third, the amount of intraindividual variability 
observed in this sample of veterans with hypertension may 
not generalize to other patient populations with hyperten-
sion or to other populations taking other medications. 
Similarly, the prevalence of reasons for nonadherence to 
antihypertensive medications across occasions may not 
generalize to other medications. Generalizability may 
also be limited by the response rate if participants differ 
in significant ways from non-participants. Finally, there 
were 31 nonadherence occasions on which no reason for 
nonadherence was endorsed. This could suggest that the list 
of reasons for nonadherence is incomplete or could reflect 
patient misunderstanding of instructions. The potential for 
error may be reduced by  introducing a skip pattern and by 
using an open-ended question to capture additional reasons 
not included in the list.
Strengths of this study include the dual conceptualization 
of extent of, and reasons for, nonadherence; the use of a reli-
able and valid measure of extent of nonadherence; and the use 
of a comprehensive measure of reasons for nonadherence. In 
addition, although a handful of participants did not receive a 
scheduled call because of database errors early in the study, 
compliance with the study was good, as indicated by a large 
proportion of participants who received 3 or 4 calls.
The f indings suggest several directions for future 
research. For one, studies should include a larger number 
of assessments of extent of, and reasons for, nonadherence 
to determine the effects on the ICC. Second, measures of 
time-varying covariates, such as daily stressors or mood, 
should be assessed to aid identification of circumstances 
that are associated with greater propensity for episodic 
nonadherence. Such measures could explain differences in 
between-person variability. Third, studies should include a 
larger number of participants to yield a sufficient number 
of nonadherence occasions for examining intraindividual 
variability in reasons for nonadherence. Finally, the recall 
period and response scale might be varied to determine the 
effects both on the proportion of individuals identified as 
nonadherent and on the ICC.
In summary, our data highlight that antihypertensive 
medication nonadherence varies just as much within patients 
as between patients, underscoring the need to assess and 
analyze nonadherence across repeated occasions. Such data, 
when coupled with information about reasons for nonadher-
ence, could improve clinical decision making, such as when 
and whether to adjust or switch medications. Such data could 
also lead to comprehensive, multifactorial interventions that 
match patient experiences with medication taking.
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